Recently dubbed the sleeping giant on the M&A front because of its noticeable lack of deal activity in the first half of the year, Abbott (NYSE: ABT) (Abbott Park, Ill.) seemed to awaken from its hibernation on Thursday with an appetite for the massive transcatheter mitral valve replacement (TMVR) market.